Ph.D., Molecular Biology, Polish Academy of Sciences, Warsaw, Poland, 1981
M.D., Molecular Medicine, Medical Academy, Poznan, Poland, 1977
 

Fellowship, Molecular Medicine, Rigshospitalet, Copenhagen, Denmark, 1979

Invited Presentations

8 Sep 2011. Malecki M. Diagnosis and Prognosis of Patients with Ovarian Cancer Based upon Molecular Profiling of Tumor Cells from Blood, Lymph, and Peritoneal Fluid. Invited Presentation. The 2nd Annual Conference: Circulating Tumor Cells, Philadelphia, PA.

9 Sep 2011. Malecki M. Molecular Biomarker Profiles of Ovarian Cancer Cells Obtained from Intraperitoneal Fluid, Lymph and Blood. Invited Presentation. The 3rd Annuank Congress: Translational Biomarkers. Philadelphia, PA.

30 Sept 2011. Malecki M. Liquid Biopsy of Ovarian Cancer: Issuing Diagnosis and Planning Therapies of Ovarian Cancers Based Upon Genome Sequencing and Gene Expression Profiling of Single Cells From Peritoneal Fluid and Blood. Invited Presentation. The 2nd Single Cell Analysis Summit, South San Francisco, CA.

10 Nov 2011. Malecki M. Molecular Profiling of Metastasizing Cancer Cells. Invited Presentation. The 3rd World International Circulating Tumor Cells Summit, San Diego, CA.

7 Dec 2011. Malecki M. Isolating single, selected chromosomes for in situ hybridization and DNA sequencing from the single, selected ovarian circulating tumor cells. Invited Presentation. Cancer Genome Sequencing Summit. Boston, MA.

02 Feb 2012. Malecki M. Liquid Biopsy of Ovarian Cancer. Invited Presentation. World International Circulating Tumor Cells Summit. San Diego, CA.

19 Feb 2012. Malecki M. Molecular Profiling of Cancer with Point-of-Care Tests. Invited Presentation at the 1st Inaugural Symposium on Point of Care Testing. San Francisco, CA.

20 Feb 2012. Malecki M. Novel biomarkers and approaches in molecular profiling of circulating tumor cells and cancer stem cells for clinical diagnoses. Invited Presentation. The 19th International Molecular Medicine Conference, San Francisco, CA. 

19 Apr 2012. Malecki M. Next generation sequencing and liquid phase in situ hybridization of isolated chromosomes. Invited Presentation. The 3rd Annual Next Generation Sequencing Summit. Boston, MA.
 

Public Relations

http://www.genengnews.com/gen-articles/ngs-advances-spawn-novel-challenges/4023/?page=1

http://www.womenshealthmag.com/health/health-updates?page=2

http://abcnews.go.com/Health/WomensHealth/Story?id=5406302&page=3

http://www.newswise.com/articles/research-may-yield-new-therapy-for-cancer

http://www.medicalnewstoday.com/articles/77799.php

http://www.prweb.com/releases/cancer_therapy/suicide_gene_therapy/prweb541972.htm

http://www.celltherapynews.com/index.cfm?act=nl&do=newsletter&nl_ID=231

http://www.newswise.com/articles/view/531642/

http://www.news-medical.net/?id=27766

http://www.beyondthecure.org/news/news.html/178/
 

• Associate Professor, SDSU, 2007-2008 (June) 
• Professor, Saba University School of Medicine, Saba, Holland, 2001-06
• Visiting Professor, University of Wisconsin, Madison, WI, 2001-06
• CEO, Phoenix Biomolecular, San Diego, CA 2001-2008 
• Director, Molecular Imaging Laboratories, University of California - San Diego, 1999-2001
• Project Coordinator, National Institutes of Health, National Biotechnology Resource, 1988-1998
• Assistant Professor, Maria Sklodowska-Curie Memorial, National Cancer Center, Warsaw, Poland, 1982-87
• Director, Molecular Imaging Laboratories, Maria Sklodowska-Curie Memorial National Cancer Center, Warsaw, Poland, 1982-87
• Assistant Professor, Polish Academy of Sciences, Warsaw, Poland, 1982
   

• Genetics, Genomics, and Gene Therapy within Ob/Gyn, Neurology, Gastrointestinal curricula at COMP.
• Introduction to Molecular Imaging within Anatomy Curriculum and Molecular Imaging of Gene Expression within MCBM curriculum at COMP.
• Biotechnology within Graduate College curriculum

Introduction
Cancer was the primary cause of deaths of women between the ages of 20-85 in the USA in 2010. Among them, more than 21,880 women were diagnosed with ovarian cancer and 13,850 of them died that year. The earliest diagnosis of cancer was the essential factor for the therapeutic outcome. This was well exemplified by the statistics showing 10-year survival rate for women diagnosed at the clinical stage IA at 84.1%, but sharply falling for those diagnosed at the stage IIIC down to 10.4%. Unfortunately, 63% of women were diagnosed after the cancers were already at the advanced stages, which led to rapid progression and death. This branded ovarian cancer “silent killer”, as the most deadly among all gynecological neoplasms.
The specific aim of our work is to reveal molecular profiles of these most deadly cancers in new and relapsing patients as the means for developing personalized targeted therapy.

Patients -  Methods
We collect the samples of peritoneal washings, primary tumors, and metastses from the patients suspected of developing or suffering symptoms of the ovarian cancers. We use recently developed techniques of molecular profiling of cancer cells [Malecki M, Szybalski W. Gene 2012, 493(1):132-9].We genetically bioengineer fluorescent and magnetic scFv targeting SSEA-4, TRA-1-60, CD30, CD133, EGFR, TfR. We isolate single cells and initiate hanging drop cultures. We analyze the cells' molecular profiles with flow cytometry (FCM), nuclear magnetic resonance (NMR), native immunoblotting (NIB), polymerase chain reaction (RT-PCR), multiphoton fluorescence (MPF), energy dispersive x-ray spectroscopy (EDXS), electron energy loss spectroscopy (EELS), and next generation sequencing (NGS).

Results
To date, with the FCM, NMR, and MPF, we revealed the populations of cells with surface expression of SSEA4, TRA1-60, CD30, CD133. With the EELS, we revealed the carcinoma cells’ ultrastructure with poorly differentiated cells and active chromatin. With the MPF, we revealed the embryonal carcinoma cells’ pluripotency by their ability to differentiate into neurons, myoblasts, and endothelium. With the RT-PCR, we revealed expression of Nanog, Oct3/4, and ABCG2 genes. With the NGS, we demonstrated the mutations present in the gene sequences coding EGFR and HER2. Using these biomarkers as the guides, we designed the novel cancer suicide gene therapy.

Conclusions
We revealed clones of pluripotent cells in the patients with recurrent, embryonal carcinomas of the ovaries. We suppose that these cells may be responsible for resisting and/or adapting to therapies. The identified molecules become biomarkers for the trials of the personalized, targeted therapy, which we currently conduct.
 

• AMERICAN MEDICAL ASSOCIATION
• AMERICAN SOCIETY FOR HUMAN GENETICS
• AMERICAN ANTIBODY SOCIETY
• SOUTHERN CALIFORNIA BIOTECHNOLOGY COUNCIL
• RHO CHI HONOR SOCIETY FOR EXCELLENCE IN TEACHING AND AS THE FACULTY ROLE MODEL 

• Malecki M, Szybalski W. Isolation of single, intact chromosomes from single, selected ovarian cancer cells for in situ hybridization and next generation sequencing. Gene. 2012, 493(1):132-9.     Open Access. [PubMed - indexed for MEDLINE] PMID:22155315. http://www.ncbi.nlm.nih.gov/pubmed/22155315

• Malecki M and Malecki B. Routing of Biomolecules and Transgenes’ Vectors in Nuclei of Oocytes. J Fertiliz In Vitro 2012, 2: 108-118. Open Access. [PubMed - indexed for MEDLINE] doi: 10.4172/2165-74

• Malecki M, Malecki B, Jackiewicz P , Cichocki A, Anderson M. Molecular profiling of pluripotent, cancer stem cells in the peritioneal washings of the patients with the advanced, recurrent embryonal carcinomas of the ovaries. Frontiers of Oncology. 2012, in press. Open Access. [PubMed - indexed for MEDLINE]